Moderna to Provide Business and Pipeline Updates at the 2022 J.P. Morgan Healthcare Conference

Rhea-AI Summary

Moderna, Inc. (Nasdaq:MRNA) will present updates on its mRNA pipeline at the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022, at 8:15 a.m. ET. CEO Stéphane Bancel will lead the presentation. A live webcast will be available on Moderna's investor website, and a recorded version will be accessible for 30 days post-event. Moderna has advanced significantly in mRNA therapeutics and vaccines, particularly in response to the COVID-19 pandemic, and maintains a strong portfolio across various disease modalities.

Positive

• CEO to provide updates on mRNA development programs at a major healthcare conference.
• Showcases the company's transformation and successful response to COVID-19.

Negative

• None.

CAMBRIDGE, MA / ACCESSWIRE / January 3, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the virtual 40^th annual J.P. Morgan Healthcare Conference on Monday, January 10^th at 8:15 a.m. ET.

A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Moderna Contact

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View source version on accesswire.com:
https://www.accesswire.com/680608/Moderna-to-Provide-Business-and-Pipeline-Updates-at-the-2022-JP-Morgan-Healthcare-Conference

FAQ

What will Moderna present at the J.P. Morgan Healthcare Conference?

Moderna will provide updates on its mRNA pipeline and development programs.

When is Moderna's presentation at the J.P. Morgan Healthcare Conference?

Moderna's presentation is scheduled for January 10, 2022, at 8:15 a.m. ET.

Where can I watch Moderna's presentation live?

The presentation will be streamed live on Moderna's investor website under 'Events and Presentations.'

What innovations has Moderna achieved in mRNA technology?

Moderna has developed therapeutics and vaccines for multiple diseases, prominently combating COVID-19.

How has Moderna's business evolved since its inception?

Moderna has grown from a research-stage company to a leader in mRNA therapeutics and vaccines with a diverse clinical portfolio.